The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
